British American Tobacco (BAT) said on Friday is ready to test its potential Covid-19 vaccine using proteins from tobacco leaves on humans, after it generated a positive immune response in pre-clinical trials, reports Reuters.
Once it gets approval from the U.S. Food and Drug administration (FDA) for the vaccine, the company plans to start testing on humans.
In April BAT announced it was developing a Covid-19 vaccine from tobacco leaves and could produce 1 million to 3 million doses per week if it got the support of government agencies and the right manufacturers.
Multiple companies from a variety of sectors have been racing to develop a vaccine for Covid-19, with some of the vaccines already in human trials. Experts have suggested that a Covid-19 vaccine could take 12-18 months to develop.
On Friday, BAT said it had submitted a pre-investigative new drug application to the FDA and that the agency had acknowledged the submission. BAT said it was also talking with other government agencies around the world about the vaccine.
The company said it has committed funds to conduct clinical trials, which it expects to start as early as late June. BAT has reportedly also invested in additional equipment to boost capacity.